The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma

Cho, Dong Hyu; Park, Ho Sung; Park, See-Hyoung; Kim, Kyoung Min; Chung, Myoung Ja; Moon, Woo Sung; Kang, Myoung Jae; Jang, Kyu Yun

doi:10.1186/s13048-015-0129-3

Journal of Ovarian Research

Table 1 Clinicopathological variables and the expression of DBC1 and BRCA1 in ovarian carcinomas

From: The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma

Characteristics		No.	Overall ovarian car		cinomas		No.	Serous c		Arcinomas
			DBC1+	P	BRCA1+	P		DBC1+	P	BRCA1+	P
Age, y	<60	71	41 (58%)	0.076	28 (39%)	0.149	45	29 (64%)	0.074	20 (44%)	0.450
	≥60	33	25 (76%)		18 (55%)		30	25 (83%)		16 (53%)
Stage	I & II	52	27 (52%)	0.015	21 (40%)	0.430	29	18 (62%)	0.128	13 (45%)	0.662
	III & IV	52	39 (75%)		25 (48%)		46	36 (78%)		23 (50%)
Tumor size, cm	≤10	68	48 (71%)	0.038	31 (46%)	0.702	56	40 (71%)	0.850	26 (46%)	0.64
	>10	36	18 (50%)		15 (42%)		19	14 (74%)		10 (53%)
LN metastasis	Absence	84	50 (60%)	0.087	37 (44%)	0.939	56	39 (70%)	0.435	28 (50%)	0.552
	Presence	20	16 (80%)		9 (45%)		19	15 (79%)		8 (42%)
Ascites	Absence	71	41 (58%)	0.076	28 (39%)	0.149	45	31 (69%)	0.462	18 (40%)	0.089
	Presence	33	25 (76%)		18 (55%)		30	23 (77%)		18 (60%)
Bilaterality	Unilateral	59	31 (53%)	0.008	24 (41%)	0.404	34	21 (62%)	0.072	16 (47%)	0.882
	Bilateral	45	35 (78%)		22 (49%)		41	33 (80%)		20 (49%)
LD Meta	Absence	76	43 (57%)	0.016	28 (37%)	0.012	52	34 (65%)	0.055	21 (40%)	0.047
	Presence	28	23 (82%)		18 (64%)		23	20 (87%)		15 (65%)
Platinum-resistance	Absence	62	38 (61%)	0.016	21 (34%)	0.014	48	32 (67%)	0.008	19 (40%)	0.043
	Presence	20	18 (90%)		13 (65%)		16	16 (100%)		11 (69%)
CA19-9	Normal	66	47 (71%)	0.060	32 (48%)	0.158	50	39 (78%)	0.341	26 (52%)	0.156
	Elevated	17	8 (47%)		5 (29%)		8	5 (63%)		2 925%)
CA125	Normal	18	7 (39%)	0.004	5 (28%)	0.121	7	4 (57%)	0.249	4 (57%)	0.630
	Elevated	75	56 (75%)		36 (48%)		61	47 (77%)		29 (48%)
Histologic grade	Low (1)	27	5 (19%)	<0.001	6 (22%)	0.007	12	4 (33%)	0.001	4 (33%)	0.267
	High (2 & 3)	77	61 (79%)		40 (52%)		63	50 (79%)		32 (51%)
Histologic type	Serous	75	54 (72%)	<0.001	36 (48%)	0.254
	Mucinous	20	3 (15%)		5 (25%)
	Endometrioid	5	5 (100%)		3 (60%)
	Clear cell	3	3 (100%)		1 (33%)
	Malignant Brenner	1	1 (100%)		1 (100%)
BRCA1	Negative	58	28 (48%)	<0.001			39	22 (56%)	0.002
	Positive	46	38 (83%)				36	32 (89%)

LN; lymph node, LD Meta; latent distant metastasis.

Back to article page

ISSN: 1757-2215

Contact us

General enquiries: journalsubmissions@springernature.com